Company intelligence / Profile preview

Lycalis

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Lycalis is a strategic consulting and interim management firm specializing in clinical drug development for the pharmaceutical industry. The company has deep expertise in CNS indications such as multiple sclerosis, epilepsy, and stroke. Its consultants have experience across biologics and small molecules from research-to-development transition through life-cycle management of blockbuster drugs. It does not develop its own pipeline of therapeutics.

Therapeutic areas: Neurology
Modalities: BiologicSmall moleculeNon-biological complex drug
Industry: Consulting

Partnerships

Not specified; works with global pharmaceutical companies and generics industry clients as part of consulting engagements.

Beyond the preview

Go deeper on Lycalis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lycalis.

Explore the full profile